Fig. 1
From: A pharmacovigilance analysis of post-marketing safety of durvalumab
Flowchart of identification of positive signals associated with durvalumab from FAERS between Q1 of 2017 and Q2 of 2024.
Fig. 1 | Scientific Reports
From: A pharmacovigilance analysis of post-marketing safety of durvalumab
Flowchart of identification of positive signals associated with durvalumab from FAERS between Q1 of 2017 and Q2 of 2024.
